Literature DB >> 17341268

Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies.

Jianming Ying1, Zifen Gao, Hongyu Li, Gopesh Srivastava, Paul G Murray, Hwee Koon Goh, Chai Yen Lim, Yajun Wang, Teresa Marafioti, David Y Mason, Richard F Ambinder, Anthony T C Chan, Qian Tao.   

Abstract

Epigenetic silencing of tumour suppressor genes (TSG) inactivates TSG functions. Previously, we identified PCDH10 as a methylated TSG in carcinomas. Here, we detected its frequent silencing and methylation in lymphoma cell lines including 100% Burkitt, 100% diffuse large B cell, 86% Hodgkin, 100% nasal natural killer/T-cell lymphoma and 1/3 of leukaemia cell lines, and in primary tumours but not in normal peripheral blood mononuclear cells or lymph nodes. PCDH10 silencing could be reversed by demethylation with 5-aza-2'-deoxycytidine. Methylation was further detected in 14% of Hodgkin lymphoma sera. Thus, PCDH10 methylation is frequently involved in lymphomagenesis and could serve as a tumour-specific biomarker.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17341268     DOI: 10.1111/j.1365-2141.2007.06512.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  20 in total

Review 1.  Regulation of Wnt signaling by protocadherins.

Authors:  Kar Men Mah; Joshua A Weiner
Journal:  Semin Cell Dev Biol       Date:  2017-08-01       Impact factor: 7.727

Review 2.  Involvement of members of the cadherin superfamily in cancer.

Authors:  Geert Berx; Frans van Roy
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-09-23       Impact factor: 10.005

Review 3.  Beyond E-cadherin: roles of other cadherin superfamily members in cancer.

Authors:  Frans van Roy
Journal:  Nat Rev Cancer       Date:  2014-01-20       Impact factor: 60.716

Review 4.  Non-clustered protocadherin.

Authors:  Soo-Young Kim; Shin Yasuda; Hidekazu Tanaka; Kanato Yamagata; Hyun Kim
Journal:  Cell Adh Migr       Date:  2011-03-01       Impact factor: 3.405

5.  Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1.

Authors:  Sanne Lugthart; Maria E Figueroa; Eric Bindels; Lucy Skrabanek; Peter J M Valk; Yushan Li; Stefan Meyer; Claudia Erpelinck-Verschueren; John Greally; Bob Löwenberg; Ari Melnick; Ruud Delwel
Journal:  Blood       Date:  2010-09-20       Impact factor: 22.113

6.  Silencing of PCDH10 in hepatocellular carcinoma via de novo DNA methylation independent of HBV infection or HBX expression.

Authors:  Song Fang; Shi-feng Huang; Ju Cao; Yang-an Wen; Li-Ping Zhang; Guo-Sheng Ren
Journal:  Clin Exp Med       Date:  2012-04-29       Impact factor: 3.984

7.  Methylated promoters of genes encoding protocadherins as a new cancer biomarker family.

Authors:  Xinbing Sui; Da Wang; Shumin Geng; Gongli Zhou; Chao He; Xiaotong Hu
Journal:  Mol Biol Rep       Date:  2011-05-21       Impact factor: 2.316

Review 8.  Aberrant expression and functions of protocadherins in human malignant tumors.

Authors:  Ming Shan; Yonghui Su; Wenli Kang; Ruixin Gao; Xiaobo Li; Guoqiang Zhang
Journal:  Tumour Biol       Date:  2016-07-24

9.  Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer.

Authors:  Gopeshwar Narayan; Luigi Scotto; Vijayalakshmi Neelakantan; Sherine H Kottoor; Ada Ho Yan Wong; Shee-Loong Loke; Mahesh Mansukhani; Bhavana Pothuri; Jason D Wright; Andreas M Kaufmann; Achim Schneider; Hugo Arias-Pulido; Qian Tao; Vundavalli V Murty
Journal:  Genes Chromosomes Cancer       Date:  2009-11       Impact factor: 5.006

10.  Genome-wide DNA methylation profiling reveals novel epigenetically regulated genes and non-coding RNAs in human testicular cancer.

Authors:  H H Cheung; T L Lee; A J Davis; D H Taft; O M Rennert; W Y Chan
Journal:  Br J Cancer       Date:  2010-01-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.